All In Biotech

Drug Trial Radar · NCT06742281

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA (CVXGA50) Intranasal COVID-19 Vaccine in Adults

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 432 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

432

Actual

Start

Dec 5, 2024

Primary completion

Jun 15, 2026

Study completion Jun 15, 2026

Sponsor

Lead sponsor
CyanVac LLCIndustry
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
Dec 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 434 healthy participants.

Conditions

  • COVID-19

Interventions

  • CVXGA (CVXGA50)Biological

    CVXGA is a recombinant parainfluenza virus type 5 (PIV5) engineered to express SARS-CoV-2 S gene from the KP.2 strain.

  • COMIRNATY®Biological

    COMIRNATY® (COVID-19 vaccine, mRNA) suspension for injection, for intramuscular use, 2024-2025 Formula (BioNTech Manufacturing GmbH \[Mainz, Germany\] and Pfizer Inc. \[New York, NY\]) will be used as the comparator vaccine for this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with symptomatic COVID-19 after boost with CVXGA (CVXGA50) compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula) to compare differences in relative vaccine efficacy.Time frame: Day 14 to Day 366 post-vaccination.

Locations

55 sites in 1 country. Site status is shown where the registry gives one.

  • Pinnacle Research Group, LLC

    Anniston, Alabama

  • Velocity Clinical Research, Phoenix

    Phoenix, Arizona

  • Velocity Clinical Research, Chula Vista

    Chula Vista, California

  • Velocity Clinical Research, San Diego

    La Mesa, California

  • Imax Clinical Trials

    La Palma, California

  • Artemis Institute for Clinical Research

    Riverside, California

  • Clinical Innovations Inc. dba CITrials

    Riverside, California

  • Avacare

    Sacramento, California

  • Collaborative Neuroscience Research, LLC

    Torrance, California

  • Velocity Clinical Research, Washington DC

    Washington D.C., District of Columbia

  • Velocity Clinical Research, Hallandale Beach

    Hallandale, Florida

  • Homestead Associates in Research, Inc

    Homestead, Florida

  • Biscayne Clinical Research

    North Miami Beach, Florida

  • Headlands Research Orlando

    Orlando, Florida

  • Best Choice Medical and Research Service

    Pembroke Pines, Florida

  • Forcare Clinical Research

    Tampa, Florida

  • Guardian Angel Research Center

    Tampa, Florida

  • Lifeline Primary Care/Avacare

    Lilburn, Georgia

  • Velocity Clinical Research, Savannah

    Savannah, Georgia

  • Clinical Research Atlanta

    Stockbridge, Georgia

  • Velocity Clinical Research, Boise

    Meridian, Idaho

  • Velocity Clinical Research, Sioux City

    Sioux City, Iowa

  • Velocity Clinical Research, Covington

    Covington, Louisiana

  • Velocity Clinical Research, Lafayette

    Lafayette, Louisiana

  • Velocity Clinical Research, New Orleans

    New Orleans, Louisiana

  • CBH Health

    Gaithersburg, Maryland

  • Advanced Primary and Geriatric Care/Avacare

    Rockville, Maryland

  • Velocity Clinical Research, Rockville

    Rockville, Maryland

  • DM Clinical Research

    Southfield, Michigan

  • Velocity Clinical Research - Norfolk

    Norfolk, Nebraska

  • Quality Clinical Research, Inc

    Omaha, Nebraska

  • Velocity Clinical Research, Omaha

    Omaha, Nebraska

  • DM Clinical Research

    Jersey City, New Jersey

  • Velocity Clinical Research, Binghamton

    Binghamton, New York

  • Rochester Clinical Research

    Rochester, New York

  • Trial Management Associates, LLC

    Wilmington, North Carolina

  • Velocity Clinical Research, Cleveland

    Beachwood, Ohio

  • Velocity Clinical Research, Mt. Auburn

    Cincinnati, Ohio

  • Velocity Clinical Research, Springdale

    Cincinnati, Ohio

  • Tekton Research, LLC

    Yukon, Oklahoma

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.